# The Appropriate Remifentanil Dose for Optimal Insertion of Laryngeal Mask Airway in Adult Patients During Induction of General Anesthesia Using Remimazolam.

> **NCT06289829** · NA · UNKNOWN · sponsor: **Yonsei University** · enrollment: 67 (estimated)

## Conditions studied

- Adult, Laryngeal Masks, Remimazolam, Remifentanil

## Interventions

- **DRUG:** remifentanil of the assigned dose
- **DEVICE:** Ambu Auragain for airway management

## Key facts

- **NCT ID:** NCT06289829
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-02
- **Primary completion:** 2025-07-29
- **Final completion:** 2025-07-29
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289829, "The Appropriate Remifentanil Dose for Optimal Insertion of Laryngeal Mask Airway in Adult Patients During Induction of General Anesthesia Using Remimazolam.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06289829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*